A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Early Parkinson's Disease
Researchers are conducting a study to learn more about a new medicine called Afamelanotide for people who have recently been diagnosed with Parkinson's disease. The main goal is to find out if the medicine is safe and to track any side effects that might happen. They will carefully check blood tests and other measures to see if there are any important changes. The study will also look at how the medicine might affect things like certain markers in the blood related to Parkinson's, inflammation, brain scans, thinking abilities, and overall well-being. This is an early-stage study, meaning it's one of the first times this medicine is being tested in humans for this condition.
At a glance
What is this study about?
This study is designed to see if a new medicine, Afamelanotide, is safe and has any positive effects for people in the early stages of Parkinson's disease. Think of it like taking a new car for a test drive – the researchers want to make sure it runs smoothly and doesn't have any unexpected problems. They will be carefully watching for any side effects, which are called 'adverse events' in medical terms. This includes checking blood tests to make sure everything is working as it should.
Beyond safety, the study also aims to explore how the medicine might impact Parkinson's. This involves looking at several different aspects. For example, they'll measure specific substances in your blood, called alpha-synuclein and inflammatory markers, which are linked to Parkinson's disease. They will also use special brain scans (MRIs) to look at changes in something called neuromelanin, and they'll check thinking skills and overall improvements in daily life.
This type of study, called a Phase IIa, is an important step in developing new treatments. It's not aiming to find a cure, but rather to gather important early information about the medicine's potential. This information will help decide if it's worth continuing to bigger studies in the future.
Key takeaways
- This study is testing a new medicine for early Parkinson's disease.
- The main aim is to check if the medicine is safe and causes side effects.
- Researchers will also look for potential effects on Parkinson's symptoms and biology.
- It's an early-stage study, so clear benefits are not guaranteed.
- Participation involves regular visits, blood tests, and scans over about eight weeks.
- You can choose to leave the study at any time.
Who may be eligible?
To be part of this study, you need to be an adult, 18 years old or older. There is no upper age limit, so people of all adult ages can be considered. Both men and women are welcome to take part in this research.
The study is specifically looking for people who have been diagnosed with Parkinson's disease, and it's particularly focused on those who are in the earlier stages of the condition. There will be other specific health requirements that the study doctors will check to make sure the medicine is suitable and safe for you to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with Parkinson's disease?
- Are you in the early stages of Parkinson's?
- Are you able to attend regular appointments for about eight weeks?
- Are you comfortable with blood tests and MRI scans?
What does participation involve?
If you decide to join this study, you would receive the study medicine, Afamelanotide. You would need to attend several appointments with the study team over approximately eight weeks. These visits will involve various checks, such as blood tests to look at how your body is reacting to the medicine and to measure certain markers. You might also have special brain scans (MRIs) and tests to assess your thinking abilities. Doctors will also check your overall health and any side effects you might experience. After receiving the medicine, there will be follow-up appointments to monitor your progress and ensure your safety.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is Afamelanotide?
Afamelanotide is the specific new medicine being tested in this study for Parkinson's disease.
What does 'early Parkinson's disease' mean?
This means the study is for people who have been diagnosed with Parkinson's disease, but are in the earlier stages of the condition.
Will this study cure my Parkinson's?
No, this is an early-stage study primarily focused on understanding the safety and potential effects of a new medicine, not a cure.
How long will I be in the study if I join?
The main part of the study involves monitoring over approximately eight weeks.
Do I have to pay to be in the study?
No, you do not have to pay to participate in a clinical trial.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.